53BP1 suppresses tumor growth and promotes susceptibility to apoptosis of ovarian cancer cells through modulation of the Akt pathway

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 1251-1257

  Hong, Shuhui ^a,b   Li, Xiaoyan ^a   Zhao, Ying ^a   Yang, Qifeng ^a   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

53BP1; Apoptosis; Cell cycle; Ovarian cancer; p Akt; Proliferation

Indexed keywords

CASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21;

53BP1 GENE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MARKER GENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84863023461     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1641     Document Type: Article

References (33)

1. Wright JW, Pejovic T, Jurevic L, Bishop CV, Hobbs T and Stouffer RL: Ovarian surface epitheliectomy in the non-human primate: continued cyclic ovarian function and limited epithelial replacement. Hum Reprod 26: 1422-1430, 2011.
2. Ovarian cancer: screening, treatment, and followup. NIH Consens Statement 12: 1-30, 1994.
3. Fong MY, McDunn J and Kakar SS: Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6: e19963, 2011.
4. Altomare DA, Menges CW, Xu J, et al: Losses of both products of the cdkn2a/arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 6: e18828, 2011.
5. Iwabuchi K, Bartel PL, Li B, Marraccino R and Fields S Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 91: 6098-6102, 1994. (Pubitemid 24188290)
6. Lowndes NF: The interplay between BRCA1 and 53BP1 influences death, aging, senescence and cancer. DNA Repair (Amst) 9: 1112-1116, 2010.
7. Mochan TA, Venere M, DiTullio RA and Halazonetis TD: 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 63: 8586-8591, 2003. (Pubitemid 38064030)
8. Cescutti R, Negrini S, Kohzaki M and Halazonetis TD: TopBP1 functions with 53BP1 in the G1 DNA damage checkpoint. EMBO J 29: 3723-3732, 2010.
9. Wu PP, Chung HW, Liu KC, et al: Diallyl sulfide induces cell cycle arrest and apoptosis in HeLa human cervical cancer cells through the p53, caspase- and mitochondria-dependent pathways. Int J Oncol 38: 1605-1613, 2011.
10. Iwabuchi K, Matsui T, Hashimoto M, Matsumoto Y, Kurihara T and Date T: Characterization of a cancer cell line that expresses a splicing variant form of 53BP1: separation of checkpoint and repair functions in 53BP1. Biochem Biophys Res Commun 376: 509-513, 2008.
11. Bartkova J, Horejsi Z, Sehested M, et al: DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26: 7414-7422, 2007. (Pubitemid 350158716)
12. Shenhua X, Lijuan Q, Hanzhou N, et al: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 18: 233-239, 1999. (Pubitemid 29359410)
13. Takeyama K, Monti S, Manis JP, et al: Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene 27: 318-322, 2008.
14. Nuciforo PG, Luise C, Capra M, Pelosi G and d'Adda di Fagagna F: Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 28: 2082-2088, 2007. (Pubitemid 47543366)
15. Du R ZH, Chen J and Jiang ZM: Relationship between loss of 53BP1 expression and clinical pathology in prostate adenocarcinoma. Chin J Clin Exp Pathol 1: 44-47, 2011.
16. Ward IM, Difilippantonio S, Minn K, et al: 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 25: 10079-10086, 2005. (Pubitemid 41572753)
17. Dai RY, Chen SK, Yan DM, et al: PI3K/Akt promotes GRP78 accumulation and inhibits endoplasmic reticulum stress-induced apoptosis in HEK293 cells. Folia Biol (Praha) 56: 37-46, 2010.
18. Miao B, Skidan I, Yang J, et al: Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci USA 107: 20126-20131, 2010.
19. Franke TF, Yang SI, Chan TO, et al: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995.
20. Hemmings BA: PH domains - a universal membrane adapter. Science 275: 1899, 1997.
21. Hemmings BA: PtdIns(3,4,5)P3 gets its message across. Science 277: 534, 1997.
22. Xu X, Zhang Y, Qu D, Jiang T and Li S: Osthole induces G2/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K/Akt pathway. J Exp Clin Cancer Res 30: 33, 2011.
23. Lee DH, Thoennissen NH, Goff C, et al: Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 306: 161-170, 2011.
24. Yingchun L, Xiujuan Q, Jinglei Q, et al: E3 ubiquitin ligase Cbl-b potentiates the apoptotic action of arsenic trioxide by inhibiting the PI3K/Akt pathway. Braz J Med Biol Res 44: 105-111, 2011.
25. Kucharzewska P, Welch JE, Svensson KJ and Belting M: The polyamines regulate endothelial cell survival during hypoxic stress through PI3K/AKT and MCL-1. Biochem Biophys Res Commun 380: 413-418, 2009.
26. Zhang F, Zheng W, Pi R, et al: Cryptotanshinone protects primary rat cortical neurons from glutamate-induced neurotoxicity via the activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Exp Brain Res 193: 109-118, 2009.
27. Rondelet B, Dewachter C, Kerbaul F, et al: Prolonged overcirculation- induced pulmonary arterial hypertension as a cause of right ventricular failure. Eur Heart J: May 23, 2011 (E-pub ahead of print).
28. Davies MA, Koul D, Dhesi H, et al: Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59: 2551-2556, 1999. (Pubitemid 29269096)
29. Cardone MH, Roy N, Stennicke HR, et al: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998. (Pubitemid 28524494)
30. Liu W, Konduri SD, Bansal S, et al: Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 281: 9837-9840, 2006. (Pubitemid 43864514)
31. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ and Arnold A: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20: 501-534, 1999. (Pubitemid 30647078)
32. Waf1/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells. Exp Mol Med 42: 395-405, 2010.
33. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3: 245-252, 2001. (Pubitemid 32201319)